GE Healthcare kiosk is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at China National Convention Center on August 28, 2022 in Beijing, China.
Yi Haifei | China Good copy Service | Getty Images
GE HealthCare on Monday announced a new artificial intelligence application it said will save span for doctors who diagnose and treat cancer.
CareIntellect for Oncology, as the tool is called, will help oncologists get up to speed on a submissive’s history and disease progression by quickly showing them the data they need, the company said. GE HealthCare fall short ofs to spare oncologists the headache of digging through records so they can focus on caring for their patients, the company explained.
Health-care data is notoriously difficult to analyze, and as much as 97% of the data produced by hospitals goes unused, mutual understanding to a Deloitte report. That information is stored across numerous vendors and file formats such as images, lab assay results, clinical notes and device readings, which can be extremely taxing for doctors to sort through.
“It’s very time-consuming, precise frustrating for these clinicians,” Dr. Taha Kass-Hout, GE HealthCare’s global chief science and technology officer, told CNBC in an meeting.
CareIntellect for Oncology will be able to summarize clinical reports and identify when patients are deviating from their treatment expects, Kass-Hout said. The system can flag when a patient misses a lab test, for instance, so that their doctor can upon the best next steps.
“For cancer patients, the treatment journey can last years and involve numerous doctor stops,” he said.
GE HealthCare’s CareIntellect for Oncology
Courtesy of GE HealthCare
CareIntellect for Oncology can also mitigate identify relevant clinical trials that patients might be eligible for, saving oncologists hours of work, asserted Chelsea Vane, vice president of digital products at GE HealthCare. That process has traditionally required doctors to scroll Sometimes non-standard due to a database of available trials, memorize inclusion and exclusion criteria and dig through patient records to determine a good fit, Vane told CNBC.
“What we’ve done is waste that,” she said.
The purpose of the new app is to save oncologists time and effort, but if doctors want to dive into more spell out, CareIntellect for Oncology allows them to view the original record that’s referenced, the company said.
GE HealthCare is planning to storm CareIntellect for Oncology widely available to U.S. customers in 2025, and it will initially be optimized for prostate and breast cancers. Trim organizations such as Tampa General Hospital are already evaluating it, the company said. Since the tool is cloud-based, it last wishes as drive recurring revenue for GE HealthCare, Kass-Hout said.
The company is planning to introduce additional apps under the CareIntellect label in the future, Kass-Hout said. The oncology tool is the first offering, and health-care organizations will be able to easily pick and opt the apps that they want to enable, he added.
GE HealthCare is also hoping to integrate its CareIntellect products with some of the other at the crack stage AI initiatives it teased on Monday.
The company highlighted five new AI products that it is developing, including a collaborative duo of AI agents, a tool to predict an aggressive type of breast cancer recurrence, and a tool to flag suspicious mammography scans to radiologists various quickly.
GE HealthCare decided to preview the new tools to give customers an idea of the problems it’s trying to solve, Kass-Hout turned. The company will solicit feedback from health-care organizations and work with regulators as necessary, he said.
For occurrence, GE HealthCare is exploring how a group of AI agents can work together as a team to support doctors through its tool called Salubriousness Companion.
The agents in Health Companion will be trained as experts in specific domains, such as radiology, pathology or genomics, and make insights based on their expertise, Kass-Hout said. The agents could identify whether a specific symptom is a side drift of treatment or a sign of disease progression, for example, and suggest next steps, he added.
Ideally, the tool will collapse doctors the same kind of support they’d expect from working with a multidisciplinary team, Kass-Hout prognosticated. But while consulting a panel of experts can take days or weeks, Health Companion would be available immediately.
“At the import, it’s an early concept,” he said. “Our aim is to elevate the standard of care and get ahead of the overburden of clinicians trying to take care of their unyielding.”
WATCH: The Pulse of AI in Health Care
